Sachin S Bhagwat
Overview
Explore the profile of Sachin S Bhagwat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hujer A, Marshall S, Mack A, Hujer K, Bakthavatchalam Y, Umarkar K, et al.
mBio
. 2023 Oct;
14(6):e0111823.
PMID: 37889005
Compared to other genera of Gram-negative pathogens, is adept in acquiring complex non-enzymatic and enzymatic resistance mechanisms thus remaining a challenge to even novel antibiotics including recently developed β-lactam and...
2.
Ahirrao V, Jadhav R, Vaidya S, Bhagwat S, Yeole R, Patel M
Biomed Chromatogr
. 2022 Feb;
36(6):e5354.
PMID: 35141944
Antibiotic susceptibility test (AST) discs are used as an in-vitro diagnostic tool to select the appropriate antibiotic to treat an infection. Generally, the concentration of the drug loaded on to...
3.
Nicolau D, Bhagwat S, Abdelraouf K
J Antimicrob Chemother
. 2021 Jun;
76(12):3326-3327.
PMID: 34179957
No abstract available.
4.
Bhagwat S, Legakis N, Skalidis T, Loannidis A, Goumenopoulos C, Joshi P, et al.
Diagn Microbiol Infect Dis
. 2021 Mar;
100(3):115327.
PMID: 33744624
Cefepime/zidebactam is in clinical development for the treatment of carbapenem-resistant Gram-negative infections. MICs of cefepime/zidebactam (1:1) and comparators against Enterobacterales (n = 563), Pseudomonas (n = 172) and Acinetobacter baumannii...
5.
Bhagwat S, Hariharan P, Joshi P, Palwe S, Shrivastava R, Patel M, et al.
J Antimicrob Chemother
. 2020 Aug;
75(12):3563-3567.
PMID: 32772098
Background: Recent reports reveal the emergence of Escherichia coli isolates harbouring a novel resistance mechanism based on four-amino-acid inserts in PBP3. These organisms concomitantly expressed ESBLs or/and serine-/metallo-carbapenemases and were...
6.
Bhagwat S, Nandanwar M, Kansagara A, Patel A, Takalkar S, Chavan R, et al.
Drug Des Devel Ther
. 2020 Jan;
13:4351-4365.
PMID: 31920285
Levonadifloxacin and its prodrug alalevonadifloxacin are novel broad-spectrum anti-MRSA agents belonging to the benzoquinolizine subclass of quinolone, formulated for intravenous and oral administration, respectively. Various in vitro and in vivo...
7.
Bhagwat S, Periasamy H, Takalkar S, Chavan R, Tayde P, Kulkarni A, et al.
Antimicrob Agents Chemother
. 2019 Jun;
63(8).
PMID: 31208999
Levonadifloxacin is a novel benzoquinolizine subclass of fluoroquinolone, active against quinolone-resistant A phase 3 trial for levonadifloxacin and its oral prodrug was recently completed. The present study identified area under...
8.
Papp-Wallace K, Nguyen N, Jacobs M, Bethel C, Barnes M, Kumar V, et al.
J Med Chem
. 2018 Apr;
61(9):4067-4086.
PMID: 29627985
Limited treatment options exist to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria possessing broad-spectrum β-lactamases. The design of novel β-lactamase inhibitors is of paramount importance. Here, three novel diazabicyclooctanes...
9.
Ambler J, Krause K, Steenbergen J, Scangarella-Oman N, Miller L, Bhagwat S, et al.
Clin Infect Dis
. 2016 Sep;
63(11):1530-1531.
PMID: 27581762
No abstract available.
10.
Bhagwat S, McGhee P, Kosowska-Shick K, Patel M, Appelbaum P
Antimicrob Agents Chemother
. 2008 Nov;
53(2):811-3.
PMID: 19029326
WCK 771 demonstrated MIC(50) and MIC(90)s of 0.03 and 1 microg/ml, respectively, against 297 recent U.S. community-acquired and hospital strains of Staphylococcus aureus, irrespective of quinolone or glycopeptide resistance. Against...